Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067601 | 1.00 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL31395611 | 1.00 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL30073354 | 1.00 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL15067956 | 0.94 | MAPT (0.44) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL15067955 | 0.94 | MAPT (0.44) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL24365089 | 0.88 | ALDH1A1 (0.38) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL12528073 | 0.85 | MAPT (0.50) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL13593456 | 0.85 | MAPT (0.50) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL16045089 | 0.84 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL14605727 | 0.84 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260092065-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | INCYTE CORP (US) | 2026-04-02 | — | — | US | disclosed |
| US-12459943-B2 | Crystalline solid forms of a BET inhibitor | INCYTE CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20250084096-A1 | TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | GENENTECH, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12152040-B2 | Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer | GENENTECH, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240360124-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240309001-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-7968718-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7820820-B2 | Method of preparation of azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-20090312549-A1 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7601715-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7598380-B2 | Method of preparation of azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2007002308-A9 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL MYERS SQUIBB CO (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007019126-A2 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032503-A1 | Method of preparation of azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2007-02-08 | — | — | US | disclosed |
| WO-2007002308-A2 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312549-A1 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | TPMT, HAVCR2, CYP3A43 | MAPT 3261/4885ALDH1A1 1413/4885CA1 4591/4885 |
| US-20250084096-A1 | TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | BRD4, BRD3, BRD2 | MAPT 1299/4885ALDH1A1 4236/4885CA1 4637/4885 |
| US-20070032503-A1 | Method of preparation of azaindole derivatives | TPMT, HAVCR2, CYP3A43 | MAPT 3261/4885ALDH1A1 1413/4885CA1 4591/4885 |
| US-12459943-B2 | Crystalline solid forms of a BET inhibitor | BRD1, BRD3, BRD2 | MAPT 612/4885ALDH1A1 4804/4885CA1 3670/4885 |
| US-20260092065-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | BRD2, BRDT, BRD1 | MAPT 264/4885ALDH1A1 4803/4885CA1 4052/4885 |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | NAT1, NISCH, AZI2 | MAPT 2127/4885ALDH1A1 1799/4885CA1 771/4885 |
| US-12152040-B2 | Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer | BRD4, BRD3, BRD2 | MAPT 1299/4885ALDH1A1 4236/4885CA1 4637/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | MAPT 4498/4885ALDH1A1 3913/4885CA1 4625/4885 |
| US-20240309001-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | BRD1, BRD3, BRD2 | MAPT 612/4885ALDH1A1 4804/4885CA1 3670/4885 |
| US-20240360124-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | MAPT 2044/4885ALDH1A1 3060/4885CA1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.